You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

169 Items
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Aug 2018
Other Name(s): Giotrif® (Boehringer Ingelheim)
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Aug 2017
Other Name(s): Zaltrap® (Sanofi-aventis)
Apr 2017
Other Name(s): Proleukin® (interleukin-2) (Novartis)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2018
Other Name(s): Alecensaro™ ()
Aug 2018
Other Name(s): MabCampath® (Sanofi Genzyme)
Apr 2016
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex® (multiple brands available)
Funding:
ODB Limited Use
  • anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
  • anastrozole - An alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
Apr 2016
Other Name(s): Erleada® ()
Nov 2018
Other Name(s): Trisenox® (Lundbeck)
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Apr 2016
Aug 2016